Cancer Drug Co. Says Efficacy Talk Didn't Mislead Investors
Gene-editing biotechnology firm Caribou Biosciences Inc. wants a proposed shareholder class action accusing it of misleading investors about the durability of its top cancer-fighting therapy to be dismissed, arguing the investor...To view the full article, register now.
Already a subscriber? Click here to view full article